At a moment in which nucleic acid vaccines are seeing a resurgence, Immunomic Therapeutics has developed a cutting-edge technology for DNA vaccination. The Company is

commercializing LAMP-Vax, a breakthrough immunomodulation platform that has the potential to transform the rapidly growing allergy and cancer immunotherapy markets.

ITI has already executed three commercial partnerships – two with Astellas Pharma and one with Geron/Asterias. The Company believes these partnerships provide important validation of its scientific platform and partnering strategy. Initial license payments received exceed $300 million and pending milestone payments exceed $55 million. Additionally, ITI will receive double-digit royalties on allergy products, a market with multi-billion-dollar potential. ITI achieved this agreement while retaining the rights to the LAMP-Vax platform for other applications, including cancer immunotherapy.